氢氯噻嗪对比安慰剂保护多囊肾病患者并改善其生活质量:HYDRO-PROTECT随机对照试验的研究方案与依据
常染色体显性多囊肾病(ADPKD)患者中,托伐普坦是唯一可用的肾脏保护药物,但排水副作用限制其耐受性。HYDRO-PROTECT研究为研究者发起的多中心、双盲、安慰剂对照随机试验,计划纳入300例快速进展的ADPKD患者,随机接受每日口服氢氯噻嗪25 mg或安慰剂共156周,主要结局为eGFR斜率。
要点
- HYDRO-PROTECT研究探讨氢氯噻嗪联合托伐普坦对ADPKD患者肾脏保护疗效和耐受性的长期影响。
- 计划纳入300例快速进展的ADPKD患者,随机1:1接受每日口服氢氯噻嗪25 mg或安慰剂共156周。
- 主要结局为eGFR斜率,次要结局包括生活质量问卷评分和24小时尿量变化。
核心结论
- HYDRO-PROTECT研究将证明氢氯噻嗪联合治疗能否改善托伐普坦对ADPKD患者的肾脏保护疗效和耐受性。
研究设计与样本
- 研究者发起的多中心、双盲、安慰剂对照随机临床试验,计划纳入300例快速进展的ADPKD患者,年龄≥18岁,eGFR>25 mL/min/1.73 m2,且在常规临床护理中稳定使用最高耐受剂量托伐普坦。
主要发现
- 既往一项初步临床研究显示,在托伐普坦基础上加用氢氯噻嗪可降低24小时尿量,并似乎增强肾脏保护疗效。
- 本研究主要结局为氢氯噻嗪组与安慰剂组相比的肾功能下降速率(以eGFR斜率表示,单位为mL/min/1.73 m2每年),采用线性混合模型分析第12周至治疗结束的所有肌酐值计算。
- 次要结局包括生活质量问卷评分(TIPS、ADPKD-UIS、EQ-5D-5L、SF-12)变化和24小时尿量变化。
关键数值与推荐
- 患者随机按1:1分配至每日口服氢氯噻嗪25 mg或匹配安慰剂,治疗156周,并联合标准治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) leads to progressive renal cyst formation and loss of kidney function in most patients. Vasopressin 2 receptor antagonists (V2RA) like tolvaptan are currently the only available renoprotective agents for rapidly progressive ADPKD. However, aquaretic side effects substantially limit their tolerability and therapeutic potential. In a preliminary clinical study, the addition of hydrochlorothiazide (HCT) to tolvaptan decreased 24-h urinary volume and appeared to increase renoprotective efficacy. The HYDRO-PROTECT study will investigate the long-term effect of co-treatment with HCT on tolvaptan efficacy (rate of kidney function decline) and tolerability (aquaresis and quality of life) in patients with ADPKD. METHODS: The HYDRO-PROTECT study is an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized clinical trial. The study is powered to enroll 300 rapidly progressive patients with ADPKD aged ≥ 18 years, with an eGFR of > 25 mL/min/1.73 m2, and on stable treatment with the highest tolerated dose of tolvaptan in routine clinical care. Patients will be randomly assigned (1:1) to daily oral HCT 25 mg or matching placebo treatment for 156 weeks, in addition to standard care. OUTCOMES: The primary study outcome is the rate of kidney function decline (expressed as eGFR slope, in mL/min/1.73 m2 per year) in HCT versus placebo-treated patients, calculated by linear mixed model analysis using all available creatinine values from week 12 until the end of treatment. Secondary outcomes include changes in quality-of-life questionnaire scores (TIPS, ADPKD-UIS, EQ-5D-5L, SF-12) and changes in 24-h urine volume. CONCLUSION: The HYDRO-PROTECT study will demonstrate whether co-treatment with HCT can improve the renoprotective efficacy and tolerability of tolvaptan in patients with ADPKD.
引用
- Bais T, Meijer E, Kramers BJ, et al. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial. Trials. 2024. PMID: 38355627. doi:10.1186/s13063-024-07952-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。